Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of GlobeImmune, Inc. (“GlobeImmune” or the “Company”) (NASDAQ:GBIM) concerning the...
LOUISVILLE, Colo., July 8, 2014 (GLOBE NEWSWIRE) -- GlobeImmune, Inc. (Nasdaq:GBIM), today announced the closing of its previously announced initial public offering of 1,725,000 shares of its...
LOUISVILLE, Colo., July 1, 2014 (GLOBE NEWSWIRE) -- GlobeImmune, Inc. (Nasdaq:GBIM), today announced the pricing of its initial public offering of 1,500,000 shares of its common stock at a price...
Clinical Trial Data to be Presented at The Liver Meeting® 2012 in Boston BOSTON, Nov. 11, 2012 - GlobeImmune, Inc., today announced Phase 2b clinical data showing that GI-5005, a Tarmogen®...
Data to be Presented Today at The Liver Meeting® 2012 in Boston BOSTON, Nov. 10, 2012 - GlobeImmune, Inc. today announced that GI-13020, an investigational therapeutic vaccine designed using the...
Five IPOs set to price Wednesday evening --Analysts see strong demand for Trulia --Capital Bank Financial moves IPO pricing to Wednesday, from Thursday -Source NEW YORK--The market's appetite for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 150 | 1.0E-6 | CS |
4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 150 | 1.0E-6 | CS |
12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 352 | 1.0E-6 | CS |
26 | -0.000199 | -99.5 | 0.0002 | 0.0002 | 1.0E-6 | 4856 | 0.00013464 | CS |
52 | -0.200499 | -99.9995012469 | 0.2005 | 0.39 | 1.0E-6 | 4031 | 0.02580415 | CS |
156 | -0.116949 | -99.9991449337 | 0.11695 | 5.46 | 1.0E-6 | 26079 | 0.72923522 | CS |
260 | 0 | 0 | 0 | 1.0E-6 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.